Neostem Inc (NBS)

0.52
0.18 25.71
NASDAQ : Health Care
Prev Close 0.70
Open 0.50
Day Low/High 0.40 / 0.60
52 Wk Low/High 0.68 / 4.26
Volume 2.19M
Avg Volume 767.60K
Exchange NASDAQ
Shares Outstanding 40.15M
Market Cap 90.34M
EPS -1.68
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

Neostem (NBS) shares are falling after the company priced is secondary offering below its previous closing price.

NeoStem Announces Dr. Merrick Ross Of MD Anderson Cancer Center As Lead Principal Investigator For Pivotal Phase 3 Trial For Metastatic Melanoma

NeoStem Announces Dr. Merrick Ross Of MD Anderson Cancer Center As Lead Principal Investigator For Pivotal Phase 3 Trial For Metastatic Melanoma

Dr. Merrick Ross to Lead NeoStem's Phase 3 Trial of Immuno-Oncology Product Candidate NBS20

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy At NeoStem

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy At NeoStem

Company on Leading Edge of Research With Experimental Therapy Targeting Specific Cancer Cells

NeoStem Stock Sees Short Interest Move 14.2% Higher

NeoStem Stock Sees Short Interest Move 14.2% Higher

The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, which shows a 388,121 share increase in total short interest for NeoStem Inc , to 3,125,226, an increase of 14.18% since 03/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

NeoStem Announces First Patient Randomized In Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

NeoStem Announces First Patient Randomized In Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

The Intus Trial is Being Conducted Under a Special Protocol Assessment (SPA) With a Primary Endpoint of Overall Survival

3 Breakout Stocks Under $10 for Your Trading Radar

3 Breakout Stocks Under $10 for Your Trading Radar

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

Amendment Adds Dedicated NeoStem Facilities and Personnel

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results

Results Support Previous Observation of Dose-Dependent Signals Across Multiple Endpoints

NBS: Insiders Vs. Shorts

NBS: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/30/2015 settlement date, and NeoStem Inc is one of the most shorted stocks of the Russell 3000, based on 15.64 "days to cover" versus the median component at 5.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

NeoStem Receives Drug Manufacture License For Irvine Facility

NeoStem Receives Drug Manufacture License For Irvine Facility

License Allows Manufacture and Distribution of Eltrapuldencel-T (NBS20) for Clinical Trial Use

NeoStem And Invetech Announce Agreement To Develop Closed Processing System For Cell Therapy Manufacturing

NeoStem And Invetech Announce Agreement To Develop Closed Processing System For Cell Therapy Manufacturing

New System Will Support Commercial-Scale Manufacturing of Cell Therapies and Other Patient-Specific Products